Risk and timing of clinical events according to diabetic status of patients treated with everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting stent: 2-year results from a propensity score matched comparison of ABSORB EXTEND and SPIRIT trials.
Carlos A H de Magalhães CamposAdriano CaixetaMarcelo FrankenAntonio L BartorelliRobert J WhitbournChiung-Jen WuHsien Li Paul KaoMohd Ali RosliDidier CarrieBernard De BruyneGregg W StonePatrick W SerruysAlexandre Abizaidnull nullPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2017)
In this largest ever patient-level pooled comparison on the treatment of diabetic patients with BRS out to two years, individuals with diabetes treated with the Absorb BVS had a similar rate of MACE as compared with diabetics treated with the Xience EES. © 2017 Wiley Periodicals, Inc.